摘要
目的探讨利妥昔单抗对视神经脊髓炎患者的治疗效果,并分析其安全性。方法视神经脊髓炎患者65例,随机分为研究组25例,对照组40例。研究组在急性期激素冲击治疗的基础上,缓解期给予利妥昔单抗治疗。对照组给予激素冲击治疗,缓解期给予环磷酰胺静滴。治疗前及治疗8周后行EDSS部分子项目评分,进行肌力检查、中国视力表检查、日常生活活动能力评定,观察利妥昔单抗治疗后的不良反应。随访1a,了解有无复发。结果治疗8周后,研究组肌力、视力、日常生活活动能力明显提高,优于对照组(P<0.05)。研究组EDSS部分子项目评分变化及功能恢复均明显优于对照组(P<0.05)。研究组用药后未出现严重不良反应。随访1a,研究组复发率明显低于对照组。结论利妥昔单抗联合激素冲击治疗视神经脊髓炎效果显著,明显改善患者视力及神经功能,降低致残率,提高日常生活能力,且安全有效,显著降低复发率。
Objective To evaluation the clinical therapeutic effect and safety of rituximab in patients with neuromyehtls optica. Methods A total of 65 patients with neuromyelitis optica were randomly divided into research group （25 cases） and control group （40 cases）. All the patients signed the informed consent before treatment. The research group was treated with rituximab in the remission phase,on the basis of acute phase hormone shock therapy. The control group was treated with hormone shock therapy,and giving Cyclophosphamide intravenous drip. The EDSS part component score, unarmed strength check, the ability to assess China＇s eye examination,daily life activities,and adverse reactions in the two groups before and 8 weeks after treatment were assessed. We conducted 1 year follow up to understand the occurrence in the two groups. Results After 8 weeks treatment, the strength,vision,daily life activities ability of research group were improved, and better than the control group （P〈0.05）. The EDSS part component score change and functional recovery of research group was better than that of control group （P〈0. 05）. TRX does not appear serious adverse reactions. The research group had a lower occurrence rate than the control group in the 1 year follow-up. Conclusion The effect of RTX combined hormone shock treatment in NMO was remarkable,can significantly improve the patient＇s vision and neural function, reduce morbidity and improve the ability of daily life. Treatment process is safe and can sig- nificantly reduce the recurrence rate.
出处
《中国实用神经疾病杂志》
2017年第16期59-62,共4页
Chinese Journal of Practical Nervous Diseases
关键词
视神经脊髓炎
利妥昔单抗
功能改善
复发率
安全性
Neuromyelitis optica
Rituximab
Function improvement
Recurrence rate
Security
